SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
GILD Analysis & Videos »
GILD: Bull or Bear?
Gilead (GILD): New potential in 4-in-1 HIV drug
GILD
+2.20%
in
17 days
Filed under: Newsletters, Gilead Sciences (GILD), Stocks to Buy "Gilead Sciences (NASDAQ: GILD) develops treatments for life-threatening diseases and specializes in drugs for HIV, the virus that causes AIDS," notes Hannah Choe. The contributing editor to Personal Finance explains, "Already the market leader in HIV antivirals, Gilead is in the beginning stages of developing Quad, the first-ever, four-in-one AIDS pill. <>"The manufacture of HIV drugs, which accounts for more than three-quarters of revenue, is Gilead's highest-grossing business. This segment has held up through the recession; in th...
|
Gilead (GILD): 'A stock for all seasons'
GILD
-1.91%
in
17 days
(closed on 10/12/09)
Filed under: Newsletters, Gilead Sciences (GILD), Stocks to Buy "Gilead Sciences (NASDAQ: GILD), one of the world's largest biotechs, is a stock for all seasons," say growth expert Alexander Green. The investment director for The Oxford Club explains, "It's a fine company with a solid balance sheet, a recession-proof business and excellent growth prospects." "Gilead focuses on three main areas, including cardiovascular conditions and respiratory diseases. (Many may have taken its anti-influenza drug Tamiflu, Letairis to treat hypertension, or Macugen to treat macular degeneration.) <><>Continue rea...
|
Biotech stock #1: Gilead Sciences (GILD)
GILD
+4.68%
in
134 days
Filed under: Gilead Sciences (GILD), Stocks to Buy  Few would argue with the claim that Gilead Sciences (NASDAQ: GILD) is the best-managed biopharma company on the planet.
It dominates the HIV treatment market and gets a 19%-plus royalty on Tamiflu, which is used to treat H1N1 (swine) flue. Gilead also has several drugs on or headed for the market to treat pulmonary disease and hard-to-treat high blood pressure. Your best strategy for life-changing profits? <>Buy the stock and sell the calls (then use the cash to buy puts on the market, which is headed down further.) Or buy long-term calls and kee...
|
FDA Calendar Updates: SNTS, CEPH, AZN, DNDN, GILD, NVO
GILD
|
|
|
-2.00%
in
230 days
<> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 112 entries through 4/6/09. The FDA Calendar includes the following information: company name, ticker...
|
Updated Clinical Trial and FDA Decision Calendars
GILD
|
|
|
+7.84%
in
37 days
(closed on 04/06/09)
<> <> <> <>  Below is a summary of updates to the FDA decision calendar since my last article, which includes a total of 90 entries through today: <> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes avai<><><><><><><><><>< />< /><><><><><><><><><><><><><><><><><><>...
|
New Index of Highly Defensive Market Cap Leaders
GILD
|
|
|
-11.62%
in
3 days
(closed on 02/28/09)
The ETF Innovators Highly Defensive Index contains 40 market cap leading companies which are based in either North America or Europe from the defensive industry groups (A-K) specified below. www.BioMedReports.com - Mike Havrilla (A) Mass Merchant Discount Retailer (1): Wal-Mart (WMT) <> <> (B) Consumer Staples (12): Coca-Cola (KO), Colgate-Palmolive (CL), Diageo (DEO), General Mills (GIS), Danone (GDNNY), Kraft Foods (KFT), Nestle (NSRGY), PepsiCo (PEP), Philip Morris International (PM), Procter & Gamble (PG), Reckitt Benckiser (RBGPF), Unilever (UN) <><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><>< />...
|
Updated Clinical Trial and FDA Decision Calendars
GILD
|
|
|
-0.58%
in
3 days
(closed on 02/25/09)
Updated FDA and Clinical Trial Calendars By Mike Havrilla on 2/22/09 BioMedReports.com Below is a summary of updates to the FDA decision calendar since my last article, which includes a total of 90 entries through today: 1.) Nuvo Research (NRIFF.PK) (Canada: NRI.TO) NDA re-submission for Pennsaid - A topical NSAID for arthritis pain/inflammation - along with Paladin Labs (Canada: PLB.TO) <> 2.) Hemispherx Biopharma (HEB) Ampligen (Poly I: Poly C12U) NDA (three month PDUFA date delay announced 2/18/09 as additional data was submitted w...
|
A More Focused Highly Defensive Index
GILD
|
|
|
+14.72%
in
80 days
(closed on 02/22/09)
<> 
The accompanying table [click to enlarge] includes an updated version of the ETF Innovators [ETFI] ETFI Highly Defensive PerformIdex of 36 companies based in the U.S., Canada, and Europe with market caps over $10B, which are the leaders by market cap in their defensive industry groups. This update includes a 10% reduction in the number of companies with an equal distribution of 12 each from consumer staples and healthcare, with the remaining 12 companies chosen from a variety of defensive industry groups.
(A) Mass Merch...
|
Achillion Pharma: Funding in Place to Advance HCV Pipeline
GILD
|
|
|
+0.18%
in
8 days
(closed on 12/03/08)
<> Achillion Pharma (ACHN) is a promising micro-cap biotech, specializing in the development of new treatments for infectious diseases, such as the multi-billion dollar market for the chronic treatment of hepatitis C. As I recently wrote , several companies in this space have been bought out at huge premiums over the past year – including an astounding premium of over 400% for a $57M buyout by GlaxoSmithKline (GSK) of hepatitis C virus [HCV] developer Genelabs (GNLB).
Since completing a $41.5M private place...
|
GILD - good
GILD
|
|
|
-14.19%
in
456 days
GILD - Got approved for Hepatitis B drugs as well as to use them on AIDS patients. The company has a very good income and lots of money to pour into research. They will continue to come out with products and should be a very good long term company. They have gone down from their 52 week high of 57.63 and are at 54.31 right now. They will probably go back up and test the 52 week high with the new news that has come out. Look to their earnings coming out over the next year - I bet they increase a fair amount.
|
Cramer on BloggingStocks: Genentech bid confirms the trend
GILD
-6.97%
in
475 days
(closed on 11/09/09)
Filed under: Deals, Market matters, Anheuser-Busch Cos (BUD), Research in Motion (RIMM), Genentech Inc (DNA), Amgen Inc (AMGN), Gilead Sciences (GILD), Stocks to Buy, Cramer on BloggingStocks  TheStreet.com's Jim Cramer says the biotechs look sweet in a bank-led slowdown.
Thank you, New York Times. Remember just a couple of weeks ago, when The New York Times wrote about how Genentech's (NYSE: DNA) (Cramer's Take) Avastin was too expensive and the stock got cracked down to $77? I know Roche did. I bet that was the last draw. The dramatic decline in the dollar plus a sentiment that has spawn...
|
Bullish on GILD ...
GILD
|
|
|
-14.60%
in
497 days
Analysts' Recommendation: Strong Buy 30 Days Ago: Strong Buy Analysts' Target: $58 Analysts' Targets Deutsche Bank Securities $63 Accumulate Thursday, June 19, 2008 Lazard Capital Markets $59 Strong Buy Thursday, April 17, 2008 Friedman, Billings, Ramsey & C $61 Hold Thursday, April 17, 2008 Rodman & Renshaw Inc. $60 Thursday, April 17, 2008 Oppenheimer & Co. Inc. $58 Outperform Thursday, April 17, 2008 RBC Capital Markets $58 Sector Perform Thursday, April 10, 2008 UBS Securities $59...
|
People Bullish on GILD
People Bearish on GILD
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on GILD |
More Resources
|
About Gilead Sciences Inc
- Answers.com
